Get in touch for more information or for support in applying for funding opportunities.
Funding Opportunities
- Drug Accelerator Awards
- BBSRC Follow-on Fund (FoF)
- MRC Integrative Toxicology Training Partnership (ITTP)
- BBSRC Flexible Talent Mobility Account (FTMA): Placement Call 2024
- 2025 Milner Consortium Call
- Cancer Research Horizons Therapeutic Catalyst Award
- Project Proposals for the Functional Genomic Screening Laboratory
Drug Accelerator Awards
The drug accelerator award preproposal form is available on our online application system. Applicants who are successful at the preproposal stage will then be invited to submit a full application via our online application system.
BBSRC Follow-on Fund
Opportunity opens: 22nd January 2025
The BBSRC Follow-on Fund (FoF) is designed to support the translation of fundamental research into practical application, including commercialisation. They want to ensure that innovation arising from BBSRC-funded research has the best opportunity to create positive impacts for society.
MRC Integrative Toxicology Training Partnership (ITTP)
Deadline: 14th February 2025
Applications will be ranked by the ITTP Steering Committee.
BBSRC Flexible Talent Mobility Account (FTMA): Placement Call 2024
Deadline for application: 26th February 2025
Funding will support incoming or outgoing placements for knowledge exchange, relationship building or skills development, including with partners in policy, industry and third sector, or placements which aim to create impact outside academia. Proposals must focus on data intensive bioscience and be within BBSRC remit, but previous/current BBSRC or UKRI funding is NOT a requirement. Interdisciplinary applications are also welcome.
Postdocs and research technical professionals are encouraged to apply as lead applicant, with a group leader/line manager as co-applicant. Applications from researchers and technicians will be assessed separately.
The funds can be used for directly incurred costs such as salary, consumables or travel. More information can be found here.
- Deadline for applications: 26 February 2025 at 16:00
- Project Duration: from 1 day up to 6 months (part-time or full time)
- Informal online 1:1 drop-in sessions are available to support applications, book now
- Contact: please email Carmen Fernandez-Posada iaa@admin.cam.ac.uk for queries and tailored advice.
2025 Milner Consortium Call
Deadline: 7th March 2025
Information webinar: 27 January 2025
Pharma partners in the Milner Therapeutics Consortium have identified topics for challenges that are a current priority for external collaboration with academics. These projects could provide a better understanding of a disease mechanism or discover and validate new therapeutic targets and can range from reagent sharing and 6-month pilots to 2-year postdoctoral funded collaborations. They are expected to lead to joint publications with the company partners.
Are you an academic at the University of Cambridge, Babraham and Wellcome Sanger Institutes? If you have an idea for a potential pre-clinical collaborative project that would benefit from industry expertise and know-how? Milner is looking for project proposals that could provide solutions to current challenges in the following areas, and applications from cross-disciplinary teams are encouraged:
Neuroscience – Immunology & Inflammation – New technologies – Infectious Disease – Reproductive Medicine – Oncology – Metabolism and Cardiovascular disease
Information webinar
To learn more, please register to attend our information and Q&A webinar on 27 January at 2pm.
For full details, to download FAQs and an application form, please visit: milner.cam.ac.uk/consortiumcall
Cancer Research Horizons Therapeutic Catalyst Award
Open ended
Cancer Research UK is uniting all their drug discovery and commercialization activity to form Cancer Research Horizons. An integral part of Cancer Research Horizons is an exciting and ambitious approach to driving therapeutic innovation. The new organization will be home to over 200 drug discovery scientists and will use cutting-edge capabilities to tackle the biggest challenges in discovering cancer drugs to help accelerate patient benefit.
To support this vision, the Therapeutic Catalyst Award is designed to kick-start exploratory drug discovery efforts in cancer, to validate and de-risk targets and technologies, and to position them for onward investment and progression. As a researcher, you can take your idea from bench to patients with a single funder and partner. Successful projects will receive up to £250,000 for up to 18 months. Informal enquiries can be directed to Matthew Farren and Neil Jones.
____________________________________________________________________________________________________________________________________________________________________________
Project Proposals for the Functional Genomic Screening Laboratory
Open now
The Milner Therapeutics Institute recently announced a new partnership with AstraZeneca and the Medical Research Council (MRC) to establish a new state-of-the-art functional genomics screening laboratory (FGSL) based at the Milner Therapeutics Institute. The call for project proposals is now open!
The call is relevant to UK-based academics, small/medium-sized enterprises (SMEs) and pharma who have complex human in vitro models, such as organoids, co-culture models, etc., amenable to arrayed CRISPR screening. Through setting up collaborations with successful applicants, the FGSL will provide academic researchers, SMEs and pharma with access to arrayed functional genomics screening to better understand the biology represented by the model and where applicable, for target identification.
Please click here to find out more about the FGSL and call for proposals.